Finance

Lists
Why is TRVI down 2,40%?
Dive Deeper
TRVI:NASDAQ
Trevi Therapeutics Inc
12,82 USD
-2,40%
(-0,32) 1D
12,82 USD
0,00% (0,00)
After hours
Closed: 8-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVI...
Open
12,96 USD
High
13,28 USD
Low
12,32 USD
Mkt. cap
1,83 млд
Avg. vol.
1,90 млн
Volume
6,35 млн
52-wk high
20,15 USD
52-wk low
9,29 USD
EPS
-0,34 USD
Beta
0,98
Shares outstanding
142,48 млн
No. of employees
34
Open
12,96 USD
High
13,28 USD
Low
12,32 USD
Mkt. cap
1,83 млд
Avg. vol.
1,90 млн
Volume
6,35 млн
52-wk high
20,15 USD
52-wk low
9,29 USD
EPS
-0,34 USD
Beta
0,98
Shares outstanding
142,48 млн
No. of employees
34
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
14 мүнөт мурун
(TRVI) Investment Strategy and Analysis (TRVI:CA)
Stock Traders Daily
Stock Traders Daily
·
4 саат мурун
Understanding Momentum Shifts in (TRVI)
About Trevi Therapeutics Inc
CEO-
Employees34
Founded2011
HeadquartersНью Хейвен, Коннектикут, Америка Кошмо Штаттары
SectorPharmaceutical industry
Analyst ratings
Based on 10 analysts giving stock ratings to TRVI in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TRVI in the last 3 months.
Highest
Current 12,82 USD
40,00 USD (+211,89%)
Average
29,00 USD (+126,12%)
Lowest
23,00 USD (+79,34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Conor MacKay
BMO Capital
Buy
Maintained
36,00 USD
+180,7%
10/06/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
24,00 USD
+87,1%
09/21/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
28,00 USD
+118,3%
08/13/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
23,00 USD
+79,3%
08/10/2026
Serge Belanger
Needham
Buy
Maintained
23,00 USD
+79,3%
08/07/2026
Ryan Deschner
Raymond James
Buy
Maintained
40,00 USD
+211,9%
08/07/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
31,00 USD
+141,7%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
30,00 USD
+133,9%
08/06/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
25,00 USD
+94,9%
08/07/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
30,00 USD
+133,9%
08/07/2026
Evan Seigerman
BMO Capital
Buy
Initiated
36,00 USD
+180,7%
07/21/2026
Unknown Analyst
BMO Capital
Buy
Initiated
36,00 USD
+180,7%
07/20/2026
William Wood
B. Riley Securities
Buy
Reiterated
31,00 USD
+141,7%
07/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
29,00 USD
+126,1%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,08 млн
6,19 млн
9,94 млн
15,15 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,83 млн
4,03 млн
4,97 млн
5,36 млн
Operating expense
13,92 млн
10,22 млн
14,91 млн
20,51 млн
Total operating expenses
13,92 млн
10,22 млн
14,91 млн
20,51 млн
Operating income
-13,92 млн
-10,22 млн
-14,91 млн
-20,51 млн
Other non operating income
-2,00 миң
-15,00 миң
-
-
EBT including unusual items
-11,82 млн
-8,33 млн
-13,21 млн
-17,82 млн
EBT excluding unusual items
-11,82 млн
-8,33 млн
-13,21 млн
-17,82 млн
Income tax expense
-15,00 миң
-16,00 миң
-20,00 миң
-19,00 миң
Effective tax rate
0,13%
0,19%
0,15%
0,11%
Other operating expenses
-
-
-
-
Net income
-11,80 млн
-8,32 млн
-13,19 млн
-17,80 млн
Net profit margin
-
-
-
-
Earnings per share
-0,08
-0,06
-0,09
-0,11
Interest and investment income
2,10 млн
1,90 млн
1,70 млн
2,70 млн
Interest expense
-
-
-
-
Net interest expenses
2,10 млн
1,90 млн
1,70 млн
2,70 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,88 млн
-10,19 млн
-14,88 млн
-20,48 млн
Gain or loss from assets sale
-
7,00 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору